



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

Sheet

1

of

15

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low

Attorney Docket No. 54763.8001.US02

--	--	--	--

U.S. PATENT DOCUMENTS


Examiner Initials	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		NUMBER	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
C801	B1	EP	174,608		_____	09/05/85	_____	
	B2	EP	351,585		_____	06/23/89	_____	
↓	B3	EP	390,323		_____	10/03/90	_____	
C802	B4	EP	475,623		_____	08/23/91	_____	
	B5	2,688,514			France (Lang = French)	09/17/93	No Expl. Relevance	
	B6	JP 04-000338			Japanese Lang Doc	01/14/92	No Expl. Relevance	
C802	B7	WO	90/05180		_____	05/17/90	_____	
✓	B8	WO	90/10448		_____	09/29/90	_____	
✓	B9	WO	91/15580		_____	10/17/91	_____	
✓	B10	WO	93/03769		_____	03/04/93	_____	
↓	B11	WO	93/19191		_____	09/30/93	_____	
C802	B12	WO	93/25224		_____	12/23/93	_____	
	B13	WO 94/06910			Previously Cited	03/31/94	IDS (2 Dec 1994)	
C801	B14	WO	94/08026		_____	04/14/94	SEARCHED MAR 26 2003	
C802	B15	WO	94/10323		_____	05/11/94	SEARCHED MAR 26 2003	
C802	B16	WO	94/18992		_____	09/01/94	SEARCHED MAR 26 2003	
	B17	WO 94/24297			FRENCH LANG DOC.	10/27/94	No Expl. of Relevance	
C804	B18	WO	94/26914		_____	11/24/94	SEARCHED MAR 26 2003	
	B19	WO 95/02697			French Lang Doc	01/26/95	No expl. of Relevance	
C804	B20	WO	95/11301		_____	04/27/95	SEARCHED MAR 26 2003	

EXAMINER		DATE CONSIDERED
<i>low</i>		<i>28 Mar 2003</i>

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low

Sheet 2 of 15 Attorney Docket No. 54763.8001.US02

FOREIGN PATENT DOCUMENTS

		Foreign Patent or Application				
<i>csl</i>	B21	WO 95/11984	_____	05/04/95	TT	
<i>csl</i>	B22	WO 95/14101	French Lang Doc	05/26/95	<i>No Expl. of Reference</i>	
<i>csl</i>	B23	WO 95/14102	French Lang Doc	05/26/95	PT	TC
<i>csl</i>	B24	WO 95/23867	French Lang Doc	09/08/95	<i>No Expl. of Reference</i>	
<i>csl</i>	B25	WO 95/30002	_____	11/09/95	PT	TC
<i>csl</i>	B26	8-508879	Japan (Japanese)	09/24/96	<i>No Expl. of Reference</i>	
<i>csl</i>					PT	TC

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.
<i>csl</i>	C1	ANDERSON, "Human Gene Therapy," <i>Nature</i> , 392:25-30, April 30, 1998.
	C2	BACCHETTI et al., "Inhibition of Cell Proliferation by an Adenovirus Vector Expressing the Human Wild Type p53 Protein," <i>International Journal of Oncology</i> , 3:781-788, 1993.
	C3	BAKER et al., "p53 Gene Mutations Occur in Combination with 17p Allelic Deletions as Late Events in Colorectal Tumorigeneses," <i>Cancer Research</i> , 50:7717-7722, December 1990.
	C4	BANDYOPADHYAY & TEMIN, "Expression of Complete Chicken thymidine Kinase Gene Inserted in a Retrovirus Vector," <i>Molecular and Cellular Biology</i> , 4(4):746-754, 1984.
	C5	BOWTELL et al., "Comparison of Expression in Hemopoietic Cells by Retroviral Vectors Carrying Two Genes," <i>Journal of Virology</i> , 62(7):2464-2473, 1988.
	C6	BROWN et al., "Increased Accumulation of p53 Protein in Cisplatin-Resistant Ovarian Cell Lines," <i>Int'l J. Cancer</i> , 55:678-684, 1993.
	C7	BROWN et al., "Mutant p53 Confers Cisplatin-Sensitivity to Resistant Ovarian Tumour Cells with Elevated Wild-Type p53," <i>Proc. Am. Assoc. Cancer Res.</i> , 34:355, Abstract #2116, 1993.
	C8	CAI et al., "Stable Expression of the Wild-Type p53 Gene in Human Lung Cancer Cells After Retrovirus-mediated Gene Transfer," <i>Hum. Gene Ther.</i> , 4:617-24, 1993.
<i>csl</i>	C9	CARTER et al., "Adenovirus Containing a Deletion of the Early Region 2A Gene Allows Growth of Adeno-Associated Virus with Decreased Efficiency," <i>Virology</i> , 191:473-476, 1992.


EXAMINER

Low

DATE CONSIDERED

26 Mar 2003

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

Sheet

3

of

15

COMPLETE IF KNOWN	
Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low

MAR 18 2003

MAR 26 2003

RECEIVED

TECH CENTER 1600-2900

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
<i>csl</i>	C10	CASEY et al., "Growth Suppression of Human Breast Cancer Cells by the Introduction of a Wild-Type p53 Gene," <i>Oncogene</i> , 6:1791-1797, 1991.	
	C11	CASSON et al., "p53 Gene Mutations in Barrett's Epithelium and Esophageal Cancer," <i>Cancer Research</i> , 51:4495-4499, 1991.	
	C12	CHANG et al., "Inhibition of Intratracheal Lung Cancer Development by Systemic Delivery of E1A," <i>Oncogene</i> , 13:1405-1412, 1996.	
	C13	CHANG et al., "Restoration of the G1 Checkpoint and the Apoptotic Pathway Mediated by Wild-Type p53 Sensitizes Squamous Cell Carcinoma of the Head and Neck to Radiotherapy," <i>Arch Otolaryngol Head Neck Surg.</i> , 123:507-215, 1997.	
<i>csl</i>	C14	COLICOS et al., "Construction of a Recombinant Adenovirus Containing the <i>denV</i> Gene from Bacteriophage T4 Which Can Partially Restore the DNA Repair Deficiency in Xeroderma Pigmentosum Fibroblasts," <i>Carconogenesis</i> , 12(2):249-255, 1991.	
	C15	CONROY, "New Gene Therapy Cleared for Use Against Lung Cancer," Biotech Daily, pp. 3-4, September 18, 1992. Reference Not Provided	
<i>csl</i>	C16	DAVIDSON et al., "A Model System for in Vivo Gene Transfer Into the Central Nervous System Using Adenoviral Vecto," <i>Nature Genetics</i> , 3:219-223, 1993.	
	C17	DEBUS et al., "Effects of Antisense Oligodeoxyribonucleotides Complementary of mRNA of the Human c-Harvey-ras oncogene on Cell Proliferation" <i>J. Cancer Res. Clin. Oncol.</i> , 116 (Suppl Part 1):5-162, Abstract #A2.037.09, 1990.	
	C18	DELAUNAY et al., "A Stable Bifunctional Antisense Transcript Inhibiting Gene Expression in Transgenic Plants," <i>Proc. Natl. Acad. Sci. USA</i> , 85:4300-4304, 1988.	
	C19	DONEOWER, "Tumor Suppressor Gene p53 and Apoptosis," <i>Cancer Bull.</i> , 46(2):161-166, 1994.	
	C20	DORIGO et al., "Sensitization of Rat Glioblastoma Multiforme to Cisplatin in Vivo Following Restroation of Wild-Type p53 Function," <i>J. Neurosurg.</i> , 88:595-540, 1998.	
<i>csl</i>	C21	EAVES et al., "The Biology of Normal and Neoplastic Stem Cells in CML," Chronic Myeloid Leukemia, 2 nd Int'l Conference, Balogna, Italy, October 4-7, 1992. From <i>Leukemia and Lymphoma</i> , 11:245-253, 1993.	

EXAMINER	DATE CONSIDERED
<i>low</i>	<i>26 Mar 2003</i>

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

O P E R A T I O N S

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)
(use several sheets if necessary)

Sheet	4	of	15	Attorney Docket No.	54763.8001.US02
-------	---	----	----	---------------------	-----------------

TECH CENTER 1600/2900
MAR 26 2003

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low

RECEIVED

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
esee	C22	EL ROUBY et al., "p53 Gene Mutation in B-cell Chronic Lymphocytic Leukemia is Associated With Drug Resistance and its Independent of MDR1/MDR3 Gene Expression," <i>Blood</i> , 82(11):3452-3459, 1993.	
	C23	EL-DEIRY et al., "WAF1, A Potential Mediator of p53 Tumor Suppression," <i>Cell</i> , 75:817-825, 1993.	
	C24	ELIYAHU et al., "p53 – A Potential Suppressor Gene?" <i>J. Cell. Biochem.</i> , UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 th Annual Meeting, Supplement 14C:264, #I 030, 1990.	
	C25	ELIYAHU et al., "Meth A Fibrosarcoma Cells Express Two Transforming Mutant p53 Species," <i>Oncogene</i> , 3:313-321, 1988.	
	C26	ELIYAHU et al., "Wild-Type p53 Can Inhibit Oncogene-Mediated Focus Formation," <i>Proc. Nat. Acad. Sci. USA</i> , 85:8763-8767, November 1989.	
	C27	FAN et al., "p53 Gene Mutations are Associated with Decreased Sensitivity of Human Lymphoma Cells to DNA Damaging Agents," <i>Cancer Res.</i> , 54(22):5824-5830, 1994.	
	C28	FEIG et al., "Somatic Activation of K-ras Gene in a Human Ovarian Carcinoma," <i>Science</i> , 223:698-701, 1984.	
	C29	FELGNER et al., "Lipfection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure," <i>Proc. Natl. Acad. Sci. USA</i> , 84:7413-7417, 1987.	
	C30	FINKEL et al., "Activation of ras Genes in Human Tumors Does Not Affect Localization Modification, or Nucleotide Binding Properities of p21," <i>Cell</i> , 37:151:158, 1984.	
	C31	FINLAY et al., "The p53 Proto-Oncogene Can Act as a Suppressor of Transformation," <i>Cell</i> , 57:1083-1093, June 1989.	
	C32	FORNACE, Jr., "Induction by Radiation of Mammalian Genes Associated with Growth-Arrest and Apoptosis, and the Role for the p53 Tumor Suppressor in Their Regulation," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:681-682, 1994.	
	C33	FOX, "Investigation of Gene Therapy Begins," <i>Nature Biotechnology</i> , 18:143-144, 2000.	
esee	C34	FRITSCHÉ et al., "Induction of Nuclear Accumulation of the Tumor-Suppressor Protein p53 by DNA-Damaging Agents," published erratum, <i>Oncogene</i> , 8:307-318, 1993.	

EXAMINER	DATE CONSIDERED
low	26 Mar 2003

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

OTPE
MAR 18 2003
SC100
SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Form PTO-1449 (Modified)
(Use several sheets if necessary)

UPDATE IF KNOWN	
Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

ECHO CENTER 1600 2000 MAR 26 2003 RECEIVED

Sheet

5

of

15

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
CSU	C35	FUJIWARA et al., "Induction of Chemosensitivity in Human Lung Cancer Cells in Vivo by Adenovirus-Mediated Transfer of the Wild-Type p53 Gene," <i>Cancer Res.</i> , 54:2287-2291, 1994.	
	C36	FUJIWARA et al., "A Retroviral Wild-Type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis," <i>Cancer Res.</i> , 53:4129-4133, 1993.	
	C37	FUJIWARA et al., "Therapeutic Effect of a Retroviral Wild-Type p53 Expression Vector in an Orthotopic Lung Cancer Model," <i>J. Natl. Cancer Inst.</i> , 86(19):1458-1462, 1994.	
	C38	GEBHARDT et al., "A Tumor Suppressor Proto-Oncogene p53 Can Block Progression Through the Cell Cycle," Association of American Physicians, American Society for Clinical Investigation, American Federation for Clinical Research, Subspecialty Meetings, Sheraton Washington Hotel, Washington, DC, May 6, 1990, pg. 447A, Abstract.	
	C39	GEORGES et al., "Prevention of Orthotopic Human Lung Cancer Growth by Intratracheal Instillation of a Retroviral Antisense K-ras Construct," <i>Cancer Research</i> , 53:1748-1746, 1993.	
CSU	C40	GJERSET et al., "Dominant Effect of Transduced Wild-Type p53 Over Endogenous Mutant p53 in Sensitizing Tumor Cells to Therapy," <i>Proceedings of the Am. Assoc. Can. Res.</i> , 36:21, 1995. (Abstract 123)	
	C41	GOBE et al., "Cell Death By Apoptosis Following X-Irradiation of the Foetal and Neonatal Rat Kidney," <i>Intl. J. Radiat. Biol.</i> , 54:567-576, 1988. Reference Not Provided	
CSU	C42	GOMEZ-FOIX et al., "Adenovirus-Mediated Transfer of the Muscle Glycogen Phosphorylase Gene into Hepatocytes Confers Altered Regulation of Glycogen Metabolism," <i>The Journal of Biological Chemistry</i> , 267(35):25129-28134, 1992.	
	C43	GOMEZ-NAVARRO et al., "Gene Therapy for Cancer Cancer," <i>European Journal of Cancer</i> , 35:864-885, 1999.	
	C44	GOYETTE et al., "Progression of Colorectal Cancer is Associated with Multiple Tumor Suppressor Gene Defects but Inhibition of Tumorigenicity is Accomplished by Correction of Any Single Defect via Chromosome Transfer," <i>Molecular and Cellular Biology</i> , 12(3):1387-1395, 1992.	
CSU	C45	GREEN, "When the Products of Oncogenes and Anti-Oncogenes Meet," <i>Cell</i> , 56:1-3, 1989.	

EXAMINER

low

DATE CONSIDERED

26 Mar 2003

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

O P E R A T I O N S C E N T E R

M A R 1 8 2 0 0 3

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
Docket Sheet	6	of	15	Application Number	08/335,461
				Confirmation Number	
				Filing Date	November 7, 1994
				First Named Inventor	Ruth Gjerset et al.
				Group Art Unit	1653
				Examiner Name	Christopher S. F. Low
				Attorney Docket No.	54763.8001.US02

T E C H C E N E R 1 0 0 P E R


M A R 2 6 2 0 0 3

R E C E I V E D

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.			T
<i>CSL</i>	C46	GREGORY et al., "Tumor Suppressor of Gene Therapy of Cancer: Adenoviral Mediated Gene Transfer of p53 into Human Tumor Cell Lines," <i>J. Cell. Biochem. Supp.</i> 18a, p. 237. <i>1994</i> .			
	C47	GRIDLEY et al., "Evaluation of Reiation Effects Against C6 Glioma in Combination with Vaccinia Virus-p53 Gene Therapy," <i>International J. Oncology</i> , 12:1093-1098, 1998.			
	C48	GRIEP and WESTPHAL, "Antisense Myc Sequences Induce Differentiation of F9 Cells," <i>Proc. Natl. Acad. Sci. USA</i> , 85:6806-6810, 1988.			
	C49	GUNNING et al., "A Human β-Actin Expression Vector System Directs High-Level Accumulation of Antisense Transcripts," <i>Proc. Natl. Acad Sci. USA</i> , 84:4831-4835, 1987.			
	C50	GUSTERSON et al., "Expression of p53 in Premalignant and Malignant Squamous Epithelium," <i>Oncogene</i> , 6:1785-1798, 1991.			
	C51	GUTIERREZ et al., "Gene Therapy for Cancer," <i>The Lancet</i> , 339:715-721, 1992.			
	C52	HANANIA et al., "Genetic Chemoprotection of Hematopoietic Cells and Genetic Chemosensitization of Breast Cancer Cells in a Mouse Cancer Gene Therapy Model," <i>Proc. Amer. Assoc. Cancer Res.</i> , Vol. 37, #2362, March 1996.			
	C53	HARPER et al., "The p21 cdk-Interacting Protein cip 1 is a Potent Inhibitor of g1 Cyclin-Dependent Kinases," <i>Cell</i> , 75:805-816, 1993.			
	C54	HARPER et al., "Enhancement of Antitumor Effects of p53 Gene Therapy by Combination with DNA-Damaging Agents" <i>Cancer Gene Therapy</i> , Vol. 3, 6, Conf. Suppl., S41-42, 1996.			
	C55	HECHT et al., "Comparison of Wildtype and Mutated p53 Protein Expression Induced by UV Irradiation of Cultured Cells," <i>FASEB Journal</i> , 8:A667, #3870, 1994.			
	C56	<i>Hematology/Oncology Clinics of North America</i> , v. 4, n. 3, <i>Bone Marrow Transplantation</i> , edited by Stephen J. Foreman, M.D., 1990. <i>Pages iv- ix.</i>			
	C57	HINDS et al., "Mutation is Required to Activate the p53 Gene for Cooperation with the ras Oncogene and Transformation," <i>Journal of Virology</i> , 63(2):739-746, February 1989.			
<i>CSL</i>	C58	HINDS et al., "The p53 Proto-Oncogene Can Suppress Transformation by Other Oncogenes, and Mutations in the Proto-Oncogene Can Activate the Gene for Transformation," <i>In: Common Mechanisms of Transformation by Small DNA Tumor Viruses</i> , Luis P. Villarreal (ed.), Chapter 7, pp. 83-101, 1989.			

EXAMINER	DATE CONSIDERED
<i>Low</i>	<i>26 Mar 2003</i>
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

Sheet 7 of 15

COMPLETE IF KNOWN	
Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763-8001.US02

RECEIVED
M A R 2 6 2003
U S P A T E N T & T R A D E M A R K O F F I C E
ENTER 16001290

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
CBK	C59	HINDS, "Biological Consequences of Mutation of the p53 Proto-Oncogene," <i>UMI Dissertation Services</i> , October 1989. (<i>ABSTRACT ONLY</i>).	
	C60	HITT et al., "Adenovirus E1A Under the Control of Heterologous Promoters: Wide Variation in E1A Expression Levels Has Little Effect on Virus Replication," <i>Virology</i> , 179:667-678, 1990.	
	C61	HODGSON, "Advances in Vector Systems for Gene Therapy," <i>Exp. Opin. Ther. Patents</i> , 5(5):549-468, 1995.	
	C62	HOLLSTEIN et al., "p53 Mutations in Human Cancers," <i>Science</i> , 253:49-53, 1991.	
	C63	HUANG et al., "Suppression of the Neoplastic Phenotype by Replacement of the RB Gene in Human Cancer Cells," <i>Science</i> , 242:1563-1566, December 1988.	
	C64	HUBER et al., "Retroviral-Mediated Gene Therapy for the Treatment of Hepatocellular Carcinoma: An Innovative Approach for Cancer Therapy," <i>Proc. Natl. Acad. Sci. USA</i> , 88:8039-8043, 1991.	
	C65	IJIRI, "Apoptosis (cell death) Induced in Mouse Bowel by 1,2-Dimethylhydrazine, Methylazoxymethanol Acetate and γ -Rays," <i>Cancer Research</i> , 49:6342-6346, 1989.	
	C66	IZANT AND WEINTRAUB "Inhibition of Thymidine Kinase Gene Expression by Anti-Sense RNA: A Molecular Approach to Genetic Analysis," <i>Cell</i> , 36:1007-1015, 1984.	
	C67	JAFFE et al., "Adenovirus-Mediated <i>In Vivo</i> Gene Transfer and Expression in Normal Rat Liver," <i>Nature Genetics</i> , 1:372-378, 1992.	
	C68	JOHNSON et al., "Transfection of a Rat Cell Line with the v-Ki-ras Oncogene is Associated with Enhanced Susceptibility to Natural Killer Cell Lysis," <i>J. Exp. Med.</i> , 162:1732-1737, 1985.	
	C69	KANEKO et al., "Induction Of Apoptosis and p53 Protein By Adriamycin and Hyperthermia In A Rat Mammary Adenocarcinoma Cell Line," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:314, #1871, 1994.	
	C70	KASID et al., "Effect of Antisense c-raf-1 on Tumorigenicity and Radiation Sensitivity of a Human Squamous Carcinoma," <i>Science</i> , 243:1354-1356, 1989.	
	C71	CASTAN et al., "p53 and Other Molecular Controls of the Response to DNA Damage," <i>J. Cell. Biochem.</i> , 9(18C):164, 1994.	
CBK	C72	CASTAN, "Discussion of Dr. Kastan's Presentation," <i>Adv. Exp. Med. Biol.</i> , 339:295-296, 1993.	

EXAMINER	DATE CONSIDERED
Low	26 Mar 2003

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Form PTO-1449 (Modified)
(Use several sheets if necessary)

MAR 18 2003

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low

Sheet

8

of

15

Attorney Docket No.

54763.8001.US02

MAR 26 2003

RECEIVED
TECH CENTER 1600
2000

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
CSF	C73	KASTAN, "p53: a Determinant of the Cell Cycle Response to DNA Damage," <i>Adv. Exp. Med. Biol.</i> , 339:291-293, 1993.	
CSF	C74	KEMP et al., "p53-Deficient Mice Are Extremely Susceptible To Radiation-Induced Tumorigenesis," <i>Nature Genetics</i> , 8(1):66-69, 1994.	
	C75	KHOKHA Rama et al. "Antisense RNA-Induced Reduction in Murine TIMP Levels Confers Oncogenicity on Swiss3T3 Cells," <i>Science</i>, 243:947-950, 1989.	
CSF	C76	KLESSIG et al., "Introduction, Stable Integration, and Controlled Expression of a Chimeric Adenovirus Gene Whose Product is Toxic to the Recipient Human Cell," <i>Molecular and Cellular Biology</i> , 4(7): 1354-1362, July 1984.	
	C77	KLINKEN et al., "Transcriptional and Post-Transcriptional Regulation of C-MYC C-MYB and p53 During Proliferation and Differentiation of Muring Erythroleukemia Cells Treated with DFMO and DMSO," <i>Exp. Cell Res.</i> , 178:185-198, 1988.	
	C78	KMIEC, "Investigators Have Been Searching For Ways To Add Corrective Genes To Cells Harboring Defective Genes. A Better Strategy Might Be To Correct The Defects." <i>American Scientist</i> , 87:240-247, 1999.	
	C79	KRIEGLER et al., In: <i>Gene Transfer and Expression: a Laboratory Manual</i> , 1990.	
CSF	C80	KRIS et al., "Expression of K-Ras Oncogene in Tumor Cell Variants Exhibiting Different Metastatic Capabilities," <i>Int. J. Cancer</i> , 35:227-230, 1985.	
	C81	KUMAR et al., "Activation of ras Oncogenes Preceding the Onset of Neoplasia," <i>Science</i>, 248:1101-1104, 1990. Reference Not provided	
CSF	C82	LAMB AND CRAWFORD, "Characterization of the Human p53 Gene," <i>Molecular and Cellular Biology</i> , 6(5):1379-1385, May 1986.	
	C83	LANE, "A Death in the Life of p53," <i>Nature</i> , 362:786-787, 1993.	
	C84	LE GAL LA SALLE et al., "An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain," <i>Science</i> , 259:988-990, 1993.	
	C85	LEE AND BERNSTEIN, "p53 Mutations Increase Resistance to Ionizing Radiation," <i>Proc. Natl. Acad. Sci. USA</i> , 90(12):5742-5746, 1993.	
CSF	C86	LEE et al., "Molecular Basis of Tumor Suppression by the Human Retinoblastoma gene," UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 th Annual Meeting, Supplement 14C, #I 001, 1990.	


EXAMINER

Low

DATE CONSIDERED

26 Mar 2003

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low

Sheet 9 of 15 Attorney Docket No. 54763.8001.US02

TECH CENTER 1600/290

MAR 26 2003

RECEIVED

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
2	C87	LESOON WOOD et al., "Systemic Gene Therapy with a Liposome-p53 Complex Reduces the Growth and Metastases of a Malignant Human Breast Cancer in Nude Mice," Proc. Annu. Meet. Am. Assoc. Cancer Res., Vol. 36, pp. A2509, 1995. <i>Reference Not Provided</i>	
CSU	C88	LEVINE et al., "The p53 Growth Suppressor Gene," UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 th Annual Meeting, Supplement 14C:264, #I 030, 1990.	
	C89	LEVINE et al., "The 1993 Walter Hubert Lecture: the Role of the p53 Tumour-Suppressor Gene in Tumorigenesis," <i>Br. J. Cancer</i> , 69(3):409-416, 1994.	
	C90	LEVINE et al., "The p53 Growth Suppressing Gene Can Inhibit Transformation by Other Oncogenes," <i>The Journal of Cell Biology</i> , The American Society for Cell Biology, Twenty-ninth Annual Meeting, Houston, Texas, November 5-9, 1989, Abstract 502.	
	C91	LOGANZO, Jr. et al., "Stabilization of p53 Protein is a Critical Response to UV Radiation in Human Melanocytes: Implications for Melanoma Development," <i>Mol. Cell. Differ.</i> , 2(1):23-43, 1994.	
	C92	LORD et al., "Macrophage Inflammatory Protein: Its Characteristics, Biological Properties and Role in the Regulation of Haemopoiesis," <i>International J. of Hematology</i> , 57:197-206, 1993.	
	C93	LOTEM AND SACHS, "Regulation by <i>bcl-2</i> , <i>c-myc</i> , and p53 of Susceptibility to Induction of Apoptosis by Heat Shock and Cancer Chemotherapy Compounds in Differentiation-Competent and Defective Myeloid Leukemic Cells," <i>Cell Growth Differ.</i> , 4(1):41-47, 1993.	
	C94	MAITY et al., "The Molecular Basis for Cell Cycle Delays Following Ionizing Radiation: a Review," <i>Radiother. Oncol.</i> , 31(1):1-13, 1994.	
	C95	MALKIN et al., "Mutant p53 Confers Tumorigenicity to a Cell Line Lacking p53: Evidence for a Second p53 Function in Tumor Formation," <i>Blood</i> , 76(10, Suppl. 1):238a, Abstract 944, 1990.	
	C96	MARSHALL, "Gene Therapy's Growing Pains," <i>Science</i> , 269:1050-1055, 1995.	
	C97	MARX, "Cell Death Studies Yield Cancer Clues," <i>Science</i> , 259:760-761, 1993.	
CSU	C98	MAXWELL et al., "Inefficiency of Expression of Luciferase Reporter from Transfected Murine Leukaemia Proviral DNA May Be Partially Overcome by Providing a Strong Polyadenylation Signal," <i>Journal of General Virology</i> , 72:1721-1724, 1991.	


EXAMINER

Low

DATE CONSIDERED

26 Mar 2003

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

Sheet 10 of 15


<u>COMPLETE IF KNOWN</u>	
Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
MAR 26 2003
160020002900

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
180	C99	McGRATH et al., "Structure and Organization of the Human <i>Ki-ras</i> Protooncogene and a Related Processed Pseudogene," <i>Nature</i> , 304:501, 1983.	
	C100	McGRATH et al., "Tumor-Specific Antisense Oligonucleotides for Controlling Cancer," Abstract No. 114.5578n, <i>Chemical Abstracts</i> , 114(7):68, 1991.	
Y80	C101	MCILWRATH et al., "Cell Cycle Arrests and Radiosensitivity of Human Tumor Cell Lines: Dependence on Wild-Type p53 for Radiosensitivity," <i>Cancer Res.</i> , 54(14):3718-3722, 1994.	
	C102	MERCER et al., "Antiproliferative Effects of Wild Type Human p53," UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 th Annual Meeting, Supplement 14C:264, #I 029, 1990.	
	C103	MERCER, "Cell Cycle Regulation and the p53 Tumor Suppressor Protein," <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2(3):251-263, 1992.	
	C104	MERCOLA et al., "Antisense RNA: Eukaryotic Controls," <i>Gene</i> , 72:253-265, 1988.	
	C105	MILLER AND VILE, "Targeted Vectors for Gene Therapy," <i>FASEB Journal</i> , 9:190-199, 1995.	
	C106	MINNA et al., "The Molecular Pathogenesis of Lung Cancer Involves the Accumulation of a Large Number of Mutations in Dominant Oncogenes and Multiple Tumor Suppressor Genes (Recessive Oncogenes)," UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 th Annual Meeting, Supplement 14C:264, #I 003, 1990.	
	C107	MIYAKE et al., "Enhancement of Chemosensitivity in Human Bladder Cancer Cells by Adenoviral-Mediated p53 Gene Transfer," <i>Anticancer Res.</i> , 18:3087-92, 1998.	
	C108	MONTENARH, "Biochemical, Immunological, and Functional Aspects of the Growth-Suppressor/Oncoprotein p53," <i>Critical Reviews in Oncogenesis</i> , (3):233-256, 1992.	
	C109	MUKHOPADHYAY et al., "Specific Inhibition of K-ras Expression and Tumorigenicity of Lung Cancer Cells by Antisense RNA," <i>Cancer Research</i> , 51:1744-1748, 1991.	
180	C110	MUNROE, "Antisense RNA Inhibits Splicing of Pre-mRNA <i>In Vitro</i> ," <i>The EMBO Journal</i> , 7(8):2523-2532, 1988.	

EXAMINER <i>Low</i>	DATE CONSIDERED <i>26 Mar 2003</i>
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low

Sheet 11 of 15 Attorney Docket No. 54763.8001.US02


RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
MAR 26 2003
1600/2900

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
CF	C111	NABEYA et al., "The Mutational Status of p53 Protein in Gastric Cancer Cell Lines Predicts Sensitivity to Chemotherapeutic Agents," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:602, Abstract #3591, 1994.	
	C112	NEVE, "Adenovirus Vectors Enter the Brain," <i>Trends Neuroscience</i> , 16(7):251-253, 1993.	
	C113	NGUYEN et al., "Delivery of the p53 Tumor Suppressor Gene into Lung Cancer Cells by an Adenovirus/DNA Complex," <i>Cancer Gene Therapy.</i> , 4(3):191-198, 1997.	
	C114	NIELSEN et al., "Efficacy of p53 Adenovirus-Mediated Gene Therapy Against Human Breast Cancer Xenografts," <i>Proc. Annu. Meet. Am. Assoc. Cancer Res.</i> , Vol. 37, pp. A2317, 1996.	
	C115	O'CONNOR et al., "Relationship between p53, Cyclin E-cdk2 Kinase Complexes and GI Arrest Induced by Ionizing Radiation in Human Cells," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:635, Abstract #3785, 1994.	
	C116	OGAWA et al., "Novel Combination Therapy For Human Colon Cancer With Adenovirus-Mediated Wild-Type p53 Gene Transfer and DNA-Damaging Chemotherapeutic Agent," <i>Int. J. Cancer</i> , 73:367-370, 1997.	
	C117	ORAZI et al., "Frequent p53 Overexpression in Therapy Related Myelodysplastic Syndromes and Acute Myeloid Leukemias: an Immunohistochemical Study of Bone marrow Biopsies," <i>Mod. Path.</i> , 6:521-525, 1993.	
	C118	ORKIN, et al, "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," December 7, 1995	
	C119	OWENS AND BOYD, "Expressing Antisense Po RNA in Schwann Cells Perturbs Myelinatino," <i>Development</i> , 112:639-649, 1991.	
e gel	C120	PALMER et al., "Efficient Retrovirus-Mediated Transfer and Expression of a Human Adenosine Deaminase Gene in Diploid Skin Fibroblasts from an Adenosine Deaminase-Deficient Human," <i>Proceedings of the National Academy of Science USA</i> , 84:1055-1059, 1987.	
	C121	PAULL et al., "The Synthesis of XTT: a New Tetrazolium Reagent that is Bioreducible to a Water-Soluble Formazan," <i>J. Heterocyclic Chem.</i> , 25:911-914, 1988. Reference Not Provided	
See	C122	PFARR et al., "Differential Effects of Polyadenylation Regions on Gene Expression in Mammalian Cells," <i>DNA</i> , 5(2):115-122, 1986.	

EXAMINER	DATE CONSIDERED
Low	26 Mar 2003

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

Sheet 12 of 15 Attorney Docket No. 54763.8001.US02

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low

TECH CENTER 1600-2000
MAR 26 2003


MAR 26 2003
REVIEWED

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.
CSL	C123	PIROLLO et al., "p53 Mediated Sensitization of Squamous Cell Carcinoma of Head and Neck to Radiotherapy," <i>Oncogene</i> , 14:1735-46, 1997.
CSL	C124	PREVEC et al., "Use of Human Adenovirus-Based Vectors for Antigen Expression in Animals," <i>J Gen. Virol.</i> , 70:429-434, 1989.
	C125	Proceedings of the American Association for Cancer Research, Vol. 36, p. 21, March 1995. Reference Not provided
CSL	C126	PROCHOWNIK et al., "c-myc Antisense Transcripts Accelerate Differentiation and Inhibit G Progression in Marine Erythroleukemia Cells," <i>Molecular and Cellular Biology</i> , 8(9):3683-3695, 1988.
	C127	RAJAN et al., "Simian Virus 40 Small-t Does Not Transactivate RNA Polymerase II Promoters in Virus Infections," <i>J. Virology</i> , 65(12):6553-6561, 1991.
	C128	RAU et al., "Response of p53 to Treatment with Actinomycin D in Human Mammary Carcinoma Cell Lines," <i>J. Cancer Res. Clin. Oncol.</i> , 120:R108, 1994.
	C129	ROSENFIELD et al., "Adenovirus-Mediated Transfer of a Recombinant α -Antitrypsin Gene to the Lung Epithelium <i>In Vivo</i> ," <i>Science</i> , 252:431-434, 1991.
	C130	ROSENFIELD et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium," <i>Cell</i> , 68:143-155, 1992.
CSL	C131	ROSS et al., "Gene Therapy in the United States: A Five-Year Status Report," <i>Human Gene Therapy</i> , 7:1781-1790, 1996.
CSL	C132	ROTH, "Gene Replacement Strategies for Therapy and Prevention of Lung Cancer," Proceedings Annual Meeting of American Assoc. Cancer Res., 35:692-3, 1994. Duplicate of IDS Filed 18 Dec 2002
PSY	C133	RYAN et al., "Cell Cycle Analysis of p53-Induced Cell Death in Murine Erythroleukemia Cells," <i>Mol. Cell. Biol.</i> , 13:711-719, 1993.
	C134	SAGER, "Tumor Suppressor Genes: The Puzzle and the Promise," <i>Science</i> , 246:1406-1412, December 1989.
	C135	SANTHANAM et al., "Repression of the Interleukin 6 Gene Promoter by p53 and the Retinoblastoma Susceptibility Gene Product," <i>Proc. Natl. Acad. Sci. USA</i> , 88:7605-7609, 1991.
CSL	C136	SANTOS et al., "Malignant Activation of a K-ras Oncogene in Lung Carcinoma but Not in Normal Tissue of the Same Patient," <i>Science</i> , 223:661-664, 1984.

EXAMINER	DATE CONSIDERED
Low	26 Mar 2003

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

Sheet 13 of 15

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low

TECH CENTER 1600
MAR 26 2003
1600/2000

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
C86	C137	SCHULER et al., "A Phase I Study of Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer.", <i>Human Gene Therapy</i> , 9:2075-2082, 1998.	
	C138	SEYAMA et al., "In Vitro and In Vivo Regulation of Liver Epithelial Cells Carrying a Metallothionein-ras T24 Fusion Gene," <i>Molecular Carcinogenesis</i> , 1:89-95, 1988.	
	C139	SHAW et al., "Induction of Apoptosis by Wild-Type p53 in a Human Colon Tumor-Derived Cell Line," <i>Proc. Natl. Acad. Sci. USA</i> , 89(10):4495-4499, 1992.	
	C140	SHENK, "Group C Adenoviruses as Vectors for Gene Therapy," in <i>Viral Vectors</i> , 1995, Academic Press.	
	C141	SHIMIZU et al., "Structure of the Ki-ras Gene of the Human Lung Carcinoma Cell Line Calu-1," <i>Nature</i> , 304:497-500, 1983.	
	C142	SLICHENMYER et al., "Loss of p53-Associated G1 Checkpoint Does Not Decrease Cell Survival following DNA Damage," <i>Cancer Research</i> , 53:4164-4168, 1993.	
✓ C86	C143	SPITZ et al., "Adenovirul mediated p53 gene therapy enhances radiation sensitivity of colorectal cancer cell lines," <i>Proc. Amer. Assoc. Cancer Res.</i> , Vol. 37, #2366, March 1996.	
	C144	STEEL, "Cyclins and Cancer: Wheels Within Wheels," <i>Lancet</i> , 343:931-932, 1994. <i>Previously cited PTO-1449 (16 Feb 1995)</i>	
✓ C86	C145	STEIN et al, "Antisense Oligonucleotides as Therapeutic Agents - is the Bullet Really Magical?" <i>Science</i> , 261:1004-1012, 1993.	
	C146	STOWERS et al., "Activation of the K-ras Protooncogene in Lung Tumors from Rats and Mice Chronically Exposed to Tetranitromethane," <i>Cancer Research</i> , 47:3212-3219, 1987.	
	C147	STRATAGENE CATALOGUE, page 39, 1988.	
	C148	STRATFORD-PERRICAUDET, "Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector," <i>Human Gene Therapy</i> , 1:241-256, 1990.	
	C149	STRATFORD-PERRICAUDET, "Feasibility of Adenovirus-Mediated Gene Transfer In Vivo," <i>Bone Marrow Transplantation</i> , 9(Suppl. 1):151-152, 1992.	
✓ C86	C150	STRATFORD-PERRICAUDET, "Gene Transfer into Animals: the Promise of Adenovirus," <i>Human Gene Transfer</i> , 219:51-61, 1991.	


EXAMINER

low

DATE CONSIDERED

26 Mar 2003

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low

TECH CENTER 1600/2900

MAR 26 2003

RECEIVED

Sheet 14 of 15 Attorney Docket No. 54763.8001.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.
<i>csl</i>	C151	STRATFORD-PERRICAUDET, "Widespread Long-Term Gene Transfer to Mouse Skeletal Muscles and Heart," <i>J. Clin. Invest.</i> , 90:626-630, 1992.
	C152	SU et al., "Transformation and Radiosensitivity of Human Diploid Skin Fibroblasts Transfected with SV40 T-Antigen Mutants Defective in RB and p53 Binding Domains," <i>Int. J. Radiat. Biol.</i> , 62(4):461-468, 1992.
	C153	SUNDARESAN et al., "Somatic Genetic Changes in Pre-Invasive Lesions in Bronchial Epithelium," ABSTRACT, <i>J. Pathol.</i> , 167(Suppl):100A, 1992.
	C154	TAKAYAMA et al., "Growth Suppression of Lung Cancer by Recombinant Adenovirus-Mediated Human p53 and p21 cDNA Transfer," <i>Proceedings Annual Meeting, American Society of Clinical Oncology</i> , 16: A1597, 1997.
	C155	TANG et al., "Potential Application of Gene Therapy to Lung Cancer," <i>Seminars in Oncology</i> , 20(4):368-373, 1993.
	C156	TAYA et al., "A Novel Combination of K-ras and myc Amplification Accompanied by Point Mutational Activation of K-ras in a Human Lung Cancer," <i>The EMBO Journal</i> , 3(12):2943-2946, 1984.
	C157	TISHLER, et al, "Increases in Sequence Specific DNA Binding by p53 Following Treatment with Chemotherapeutic and DNA Damaging Agents, <i>Cancer Research</i> , 53:2212-2216, 1993.
	C158	TOFTGARD et al., "Proto-Oncogene Expression During Two-Stage Carcinogenesis in Mouse Skin," <i>Carcinogenesis</i> , 6(4):655-6657, 1985.
	C159	TSENG AND BROWN, "Antisense Oligonucleotide Technology in the Development of Cancer Therapeutics," <i>Cancer Gene Therapy</i> , 1(1):65-71, 1994.
	C160	VARGHESE et al., "The Role of p53 and ras Genes in Radiation-Induced Transformation of Immortalized Human Epidermal Keratinocytes," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:91, Abstract #542, 1994.
	C161	VERMA et al, "Gene Therapy - Promises, Problems, and Prospects," <i>Nature</i> , 389:239-242, 1997
	C162	VOGELSTEIN et al., "Genetic Alterations Accumulate During Colorectal Tumorigenesis," UCLA Symposia on Molecular and Cellular Biology, February 3 - March 11, 1990, Abstracts, 19 th Annual Meeting, <i>J. Cell. Biochem.</i> , Supplement 14C:264, #I 004, 1990.
<i>csl</i>	C163	VOGELSTEIN et al., "Genetic Alterations During Colorectal-Tumor Development," <i>The New England Journal of Medicine</i> , 319(9):525-532, 1988.

EXAMINER	DATE CONSIDERED
<i>low</i>	<i>26 Mar 2003</i>

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

COMPLETE IF KNOWN	
Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

Sheet

15

of

15

SEARCH CENTER 1600/2900

MAR 26
2003

RECEIVED

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	C164	WAHRAN et al., <i>Tumour Biol.</i> 6:41-56, 1985. <i>Document not provided</i>	
GJSL	C165	WANG AND FINER, "Second-Generation Adenovirus Vectors," <i>Nature Medicine</i> , 2:714-716, June 6, 1996.	
	C166	WEINBERG, "Tumor Suppressor Genes," <i>Science</i> , 254:1138-1146, 1991.	
	C167	WILKINSON et al., "Constitutive and Enhanced Expression from the CMV Major IE Promoter in a Defective Adenovirus Vector," <i>Nucleic Acids Research</i> , 20(9):2233-2239, 1992.	
	C168	WILLS AND MENZEL, "Adenovirus Vectors for Gene Therapy of Cancer," <i>Journal of Cellular Biochemistry</i> , Supp. 17E, p. 204, Abstract #S216, March-April 1993.	
	C169	WILLS et al., "Tumor Supressor Gene Therapy of Cancer: Adenoviral Mediated Gene Transfer of p53 and Retinoblastoma cDNA into Human Tumor Cell Lines," <i>J. Cell. Biochem. Supp.</i> 18c, p. 204. (1994)	
	C170	WINTER AND PERUCHO, "Oncogene Amplification During Tumorigenesis of Established Rat Fibroblasts Reversibly Transformed by Activated Human ras Oncogenes," <i>Molecular and Cellular Biology</i> , 6(7):2562-2570, 1986.	
184	C171	XU et al., "Parental Gene Therapy with p53 Inhibits Human Breast Tumors <i>In Vivo</i> Through a Bystander Mechanism Without Evidence of Toxicity," <i>Human Gene Therapy</i> , 8:177-185, 1997.	
X	C172	YAMADA AND OHYAMA, "Radiation and Apoptosis," <i>Gan To Kagaku Ryofo</i> , 21(5):602-607, 1994. (Japanese Language Document)	
184	C173	ZHANG AND ROTH, "Propagation of Recombinant p53 Adenovirus and Evaluation of its Effect on Human Lung Cancer Cell Lines," <i>The Fourth Meeting o the Molecular Basis of Cancer</i> , June 1993.	
X	C174	ZHANG et al., "Generation and Identification of Recombinant Adenovirus by Liposome-Mediated Transfection and PCR? Analysis," <i>BioTechniques</i> , 15(5):868-872, 1993. <i>Reference Not provided</i>	
X	C175	ZHANG et al., "High Efficiency Gene Transfer and High Level Expression of Wild Type p53 in Human Lung Cancer Cells Mediated by Recombinant Adenovirus," <i>Cancer Gene Therapy</i> , 1:5-13, 1994. <i>Reference Not provided</i> .	
184	C176	ZHOU AND DUESBERG, "myc Protooncogene Linked to Retroviral Promoter, but Not the Enhancer, Transforms Embryo Cells," <i>Proceedings of the National Academy of Science USA</i> , 85:2924-2928, 1988.	

EXAMINER

Low

DATE CONSIDERED

26 Mar 2003

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).